细胞粘附分子CD11a、CD49d在再生障碍性贫血中的检测及应用

目的 探讨细胞粘附分子(CAMs)CD11a、CD49d在再生障碍性贫血(AA)患者的表达特点及临床应用.方法 采用碱性磷酸酶抗碱性磷酸酶法(APAAP法)测定26例慢性再生障碍性贫血(CAA)、6例急性再牛障碍性贫血(AAA)患者和20例非血液病的外科手术患者骨髓及外周血单个核细胞(MNC)粘附分子CD11a、CD49d表达的阳性细胞百分率.结果慢性再生障碍性贫血患者骨髓及外周血MNC的CD11a及骨髓MNC的CD49d表达的阳性细胞百分率较对照组降低,外周血MNC的CD49d表达与对照组无显著差异.急性再生障碍性贫血患者骨髓及外周血MNC的CD11a及骨髓、外周血MNC的CD49d表达与对照组无显著差异.结论 细胞粘附分子表达在急、慢性再生障碍性贫血有所不同.细胞粘附分子表达降低在慢性再生障碍性贫血的发病中发挥了一定作用,纠正再障患者粘附分子的异常表达,可以改善其骨髓造血动能.     

当归注射液对免疫诱导再生障碍性贫血小鼠CD34＋细胞及其Fas抗原表达的影响

背景:前期实验已证实当归注射液能改善再生障碍性贫血小鼠骨髓微环境,促进造血细胞增生.能增加细胞周期蛋白D2表达,促进细胞从G1→S期的转换.目的:拟证实当归注射液对免疫诱导再生障碍性贫血小鼠CD34+细胞及其Fas抗原表达的影响.设计、时间和单位:完全随机区组设计的细胞分子学实验,于2005-11/2006-04在武汉大学人民医院儿科研究所进行.材料:选用8～12周龄雌性(H-2a、MLSbBalb/c小鼠作为受体,制作再生障碍性贫血模型.选用DBN2小鼠(H-2a、MLsa)8～10周龄作为供体.方法:将雌性Balb/c小鼠随机分为3组:对照组、模型组和治疗组,每组8只.模型组和治疗组动物建立再生障碍性贫血模型.对照组不经照射.于造模当天开始.模型组和对照组腹腔注射无菌生理盐水10 mL(kg·d),治疗组腹腔注射当归沣射液10mL/(kg·d),1次/d,连续12d.主要观察指标:于第12天每只小鼠采集尾静脉血测外周血自细胞计数,取出股骨,计数骨髓单个核细胞.酶联免疫法检测肿瘤坏死因子α表达水平,经流式细胞仪检测骨髓单个核细胞CD34+细胞及CD34+细胞Fas抗原表达.结果:模犁组和治疗组小鼠外周血白细胞及骨髓单个核细胞计数均明显低于对照组.治疗组明显高于模型组(P<0.01).模型组CD34+抗原表达水平明显低于对照组,治疗组CD34+抗原表达水平明显高于模型组(P<0.01).已接近对照组水平.对照组CD34+细胞Fas抗原表达最低,模型组Fas抗原表达明显升高,与对照组比较差异有显著性意义(P<0.01),表明细胞增殖受影响.治疗组Fas抗原的表达低于模型组(P<0.01).模型组小鼠肿瘤坏死因子α表达明显高于对照组,治疗组明显低于模型组(P<0.01).结论:当归注射液可能通过降低负调控因子肿瘤坏死因子α水平,减少细胞凋亡,促进再生障碍性贫血小鼠造血细胞的增殖.     

正常人骨髓、脐血及动员后外周血CD^＋34细胞粘附分子的研究

目的探讨正常人骨髓、脐血及动员后外周血CD34+细胞粘附分子的表达及外周血干细胞动员的可能机制.方法采用CD34+MultiSortKit免疫磁珠分离系统,分离纯化出正常人骨髓、脐血及动员后外周血CD34+细胞,流式细胞术检测其纯度,选择与CD34+细胞相关的粘附分子CD44、CD11a、CD18、CD49d、CD54、CD58及CD62L,进行免疫荧光标记及短期液体培养后再行免疫荧光标记,流式细胞术检测.结果动员后外周血CD34+细胞粘附分子表达CD44为(92.7±2.2)%[骨髓(93.1±2.3)%]、CD11a为(56.3±6.0)%[骨髓(61.8±7.8)%]、CD18为(65.2±6.0)%[骨髓(70.6±7.5)%]、CD49d为(39.4±7.2)%[骨髓(66.9±5.1)%]、CD54为(20.9±4.1)%[骨髓(24.1±3.8)%]、CD58为(77.9±5.8)%[骨髓(81.9±5.6)%]及CD62L为(45.9±5.6)%[骨髓(63.9±4.3)%],其表达均较骨髓为低,尤以CD49d和CD62L为著.脐血CD34+细胞CD11a为(55.5±6.5)%、CD18为(66.7±7.5)%、CD44为(90.3±4.0)%、CD49d为(63.7±6.7)%、CD62L为(50.8±5.9)%,其表达亦较骨髓为低,尤以CD62L为著,但脐血CD54的表达[(29.1±4.9)%]较骨髓及动员后外周血为高,尤较动员后外周血为著.结论不同来源CD34+细胞粘附分子表达存在差异,外周血细胞动员的机制可能与粘附分子的表达下调有关.     

GPI锚定蛋白抗体CD55、CD59及RET在贫血诊断中的意义探讨

目的检测几类贫血患者外周血中红细胞和中性粒细胞膜上糖化磷脂酰肌醇（GPI）连接的补体调节蛋白CD55和CD59表达情况,综合分析各类贫血中网织红细胞（RET）的变化特点,探讨他们在贫血中的诊断价值。方法荧光标记的CD55、CD59单克隆抗体,用流式细胞技术及亚甲蓝活体染色检测,30例正常人、25例缺铁性贫血（IDA）、26例巨幼细胞性贫血（MA）、27例自身免疫溶血性贫血（AHA）,27例再生障碍性贫血、21例再生障碍性贫血-阵发性睡眠性血红蛋白尿症（AA-PNH）、30例阵发性睡眠性血红蛋白尿症（PNH）患者外周血中CD55^-和CD59^-红细胞和中性粒细胞的百分率及REF值。结果正常人CD55^-、CD59^-红细胞和中性粒细胞的百分率均〈5％,44％的IDA患者CD55^-、CD59^-红细胞百分率在5％-20％之间,中性粒细胞的百分率〈5％,MA及AHA患者CD55^-、CD59^-红细胞和中性粒细胞百分率均〈5％。33％AA患者CD55^-、CD59^-细胞百分率在5％-15％之间。PNH及AA-PNH患者CD55^-、CD59^-细胞百分率均〉11％。与正常对照组比较,各类贫血间REY值差异显著（P〈0．01）。结论IDA、AA、AA—PNH、及PNH外周血中CD55^-、CD59^-百分率较正常对照组有不同程度增加,PNH最为明显,IDA变化最小。联合RET检查有助于各类贫血的诊断、鉴别诊断及愈后判断。     

慢性再生障碍性贫血患者细胞黏附分子CD11a、CD49d检测及临床应用

细胞黏附分子（cellular adhesion molecules,CAMs）是一类介导细胞与细胞、细胞与细胞外基质间黏附作用的膜表面糖蛋白,参与人体的多种生理与病理过程。近几年来,再生障碍性贫血（AA）其病因及发病机理一直未完全阐明,虽然有关AA免疫分子方面尤其细胞因子方面的研究较为深入,且部分已应用于临床,但有关细胞黏附分子方面的临床研究较少。我们对本院20例慢性再生障碍性贫血（chronic aplastic anemia,CAA）患者治疗前后细胞黏附分子CD11a、CD49d进行检测,以探讨其表达特点及临床意义。     

丹参素对小鼠外周血造血干细胞动员作用的研究

目的:探讨丹参素对小鼠外周血造血干细胞的动员作用及其对小鼠外周血细胞和骨髓基质细胞黏附分子的影响。方法:30只BALB/c小鼠随机分为三组:丹参素组、G-CSF组、生理盐水组,腹腔注射d1～d7,每日1次,第2～8天,采用外周血WBC和MNC计数、流式细胞术、造血祖细胞体外培养、免疫细胞化学等检测各组给药后对外周血WBC、MNC、CD34+细胞、CD49d阳性细胞、CFU-GM、CFU-MK、CFU-E的产率及小鼠骨髓基质细胞VCAM-1阳性细胞百分率的影响。结果:丹参素组给药第7天外周血WBC、MNC数量达到高峰,分别为给药前的3倍和3.5倍;丹参素组外周血CD34+、CD49d阳性细胞及骨髓基质细胞VCAM-1阳性细胞百分率分别为(1.03±0.24)%、(12.59±2.64)%和(50.86±8.77)%,均明显高于生理盐水组(P<0.05);其CFU-GM、CFU-MK和CFU-E产率分别为(14.90±2.88)%、(12.50±4.06)%和(16.10±6.36)%,均明显高于生理盐水组(P<0.01)。结论:丹参素对小鼠外周血造血干细胞有一定的动员作用,且这一作用可能与其上调小鼠外周血细胞和骨髓基质细胞黏附分子的表达有关。     

骨髓间充质干细胞上调再生障碍性贫血患者CD4~+ CD25~+ Foxp3~+调节性T细胞的临床研究

目的:初步探讨再生障碍性贫血(AA)患者外周血CD4+CD25+Foxp3+调节性T细胞(Treg)的表达及临床意义;探讨临床使用异体骨髓间充质干细胞(MSC)治疗对CD4+CD25+Foxp3+Treg表达的影响。方法:(1)流式细胞仪检测13例重型再生障碍性贫血(SAA),17例慢性再生障碍性贫血(CAA)及10例健康对照者外周血CD4+CD25+Foxp3+Treg表达;(2)检测7例AA患者MSC治疗前后外周血CD4+CD25+Foxp3+Treg表达。结果:(1)AA患者外周血CD4+CD25+Foxp3+Treg表达明显低于健康对照者(P<0.01);(2)SAA患者CD4+CD25+Foxp3+Treg表达较CAA者低(P<0.05);(3)MSC治疗后AA患者外周血CD4+CD25+Foxp3+Treg表达升高(P<0.05)。结论:(1)AA患者存在外周血CD4+CD25+Foxp3+Treg表达减低,其表达异常可能参与AA的发病;(2)CD4+CD25+Foxp3+Treg表达在SAA患者更低,提示其表达水平可能可以作为判断AA病情轻重的指标;(3)MSC治疗可上调AA患者CD4+CD25+Foxp3+Treg表达,为MSC纠正AA患者的免疫异常提供了临床依据。     

丹参素、川芎嗪对小鼠外周血造血干细胞动员作用的研究

目的探讨丹参素、川芎嗪对小鼠外周血造血干细胞的动员作用及其对小鼠外周血细胞和骨髓基质细胞粘附分子的影响。方法40只BALB／c小鼠，随机分为4组：丹参素组[300mg／（kg·d）]、川芎嗪组E50mg／（kg·d）]、rhG-CSF组[250μg／（kg·d）]、生理盐水组，腹腔注射d1～7，1次／d，第8天，采用外周血WBC、MNC计数、流式细胞术、造血祖细胞体外培养、免疫细胞化学等检测各组给药后对外周血WBC、MNC、CD34^＋细胞、CD49d阳性胞、CFU-GM、CFU-MK、CFU-E的产率及小鼠骨髓基质细胞VCAM-1阳性细胞百分率的影响。结果丹参素组给药第7天外周血WBC、MNC数量达到高峰，分别为给药前的3倍和3．4倍；丹参素组外周血CD34^＋、CD49d阳性细胞及骨髓基质细胞VCAM-1阳性细胞百分率分别为（1．03±0．24）％、（12．59±2．64）％和（50．86±8．77）％，均明显高于生理盐水组（P〈0．05）；其CFU-GM、CFU-MK和CFU-E产率分别为（14．90±2．88）％、（12．50±4．06）％和（16．10±6．36）％，均明显高于生理盐水组（P〈0．01）；川芎嗪组给药第7天外周血WBC、MNC数量达到高峰，分别为给药前的3．2倍和3．9倍；川芎嗪组外周血CD34^＋、CD49d阳性细胞及骨髓基质细胞VCAM-1阳性细胞百分率分别为（O．86±0．42）％、（12．91±2．84）％和（48．47±7．87）％，均明显高于生理盐水组（P〈0．05）；川芎嗪组CFU-GM、CFU-MK和CFU-E产率分别为（53．10±9．63）％、（20．40±5．36）％和624．50±5．35）％，均明显高于生理盐水组（P〈0．01）。结论丹参素、川芎嗪对小鼠外周血造血干细胞有一定的动员作用，且这一作用可能与其上调小鼠外周血细胞和骨髓基质细胞粘附分子的表达有关。     

高剂量化疗联合自体外周血造血干细胞移植时骨髓及外周血采集物中CD34+细胞黏附分子的表达

本研究的目的是应用免疫荧光直接三色标记和流式细胞术(FCM)，观测高剂量化疗(HDC)联合自体外周血造血干细胞移植(APBSCT)时不同阶段的骨髓及外周血CD34^ 细胞，表达CD54、CD49d和CD62L的情况，探讨不同来源的CD34^ 细胞表达黏附分子的差异及其临床意义。将动员前、干细胞采集后和移植结束而骨髓重建后的骨髓样本及每次外周血单个核细胞样本，以CD34-PE和CD45-PerCP标记的同时，分别加CD54-FITC、CD49d—FITC、CD62L—FITC直接三色荧光标记．应用FACS测定CD34^ 细胞及各黏附分子表达情况，并比较不同时段骨髓中各类黏附分子表达的差异，以及外周血造血干细胞采集物与动员前骨髓中各类黏附分子表达的差异。结果表明．动员前、采集后及移植重建后骨髓中CD34^ 细胞对CD54、CD49d和CD62L表达的变化无统计学差异；造血干细胞第1和第2次采集物之间CD34^ 细胞对CD54、CD49d和CD62L的表达变化也无统计学差异；而造血干细胞采集物中CD34^ 、CD49^ 细胞较之动员前骨髓中CD34^ CD49d^ 细胞明显减少(P=0．001)。结论：化疗联合粒细胞集落刺激因子(G-CSF)的动员方法，可使骨髓中CD34^ 细胞的CD49d表达下调，并使之动员而进入外周血，移植重建后骨髓中CD34^ 细胞的CD49d表达趋于正常，其进一步的临床意义有待更多的病例积累予以阐明。     

再生障碍性贫血患者幼红巨噬细胞黏附蛋白基因表达的探讨

目的:探讨再生障碍性贫血患者治疗前后骨髓和外周血标本单个核细胞中幼红巨噬细胞黏附蛋白(EMP)基因的表达。方法:抽取18例再生障碍性贫血患者治疗前后的骨髓和外周血标本,另选10例健康骨髓捐献者为正常对照组,均分离骨髓和外周血单个核细胞,分别提取细胞总RNA,用RT-PCR方法检测EMP mRNA。结果:再生障碍性贫血患者的骨髓和外周血中EMP表达水平分别显著低于正常对照组(P<0.05),而治疗后的表达显著增高(P<0.05)。结论:EMP mRNA可为再生障碍性贫血的诊断与治疗提供依据。     

CD34+ cells and CD34+CD38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow, and cord blood

As suggested previously, a down-regulation of some cellular adhesion molecules (CAMs) on CD34(+) hematopoietic progenitor cells (HPC) may contribute to their egress from bone marrow (BM) to peripheral blood (PB) by decreasing their adhesion to BM stromal cells. Besides counting the percentage of CAM-positive cells, we decided to define clearly the antigen density (AgD) of the CAM on mobilized- and steady-state CD34(+) HPC using QIFIKIT calibration beads. Five sources of cells were compared: PB and BM from normal donors (nPB, nBM) cord blood (CB), mobilized PB obtained from leukapheresis products (LKP), and mobilized BM (mBM) samples. In our study the CAM-AgD was the lowest on CD34(+) cells in LKP which, on the contrary, contained the highest percentage of CD117(+), CD54(+), CD58(+) cell subsets. As for CB, a greater proportion of CD44(+) and CD62L(+) cells was observed in LKP than in other products. The LKP-CD34(+) cell population contained a greater percentage of CD11a(+) cells when compared to mBM, but the lowest percentage of CD49d(+) and CD49e(+) cells when compared to all products. The proportion of the CD34(+)CD38(-) immature subset expressing CD11a, CD44, CD54, or CD62L was greater in LKP than in mBM; the CD62L-AgD was higher in LKP than in mBM. This quantitative analysis clearly showed a downregulation of all CAM on LKP-CD34(+). The CD44, CD62L, CD11a, and CD54 AgD decrease appears to be specifically involved in the egress of the CD34(+) subsets into PB. The control of antigen density of these adhesion molecules is likely to be clinically important for effective mobilization of HPC as well as for rapid engraftment following HPC transplant.     

外周血CD34+细胞绝对计数可靠预示自体外周血干细胞采集效果

目的　为确定外周血CD34+细胞绝对计数能否可靠预示自体外周血干细胞的采集效果。方法　用流式细胞仪ProCOUNT方法对采集的 2 5份次移植物和采集当天外周血行CD34+细胞绝对计数 ,同时做外周血常规检查和移植物集落形成单位 (CFU)计数 ,每份次移植物以CD34+/kg ,单个核细胞 (MNC) /kg,粒 巨噬细胞集落形成单位 (CFU GM) /kg ,红细胞集落形成单位 (CFU E) /kg等为指标 ,与患者采集当天的外周血CD34+细胞绝对计数、CD34+细胞百分比、WBC ,MNC ,中性粒细胞(NEU)或血小板 (PLT)等各项指标进行相关分析和逐步回归分析。结果　 ( 1)Spearman相关分析结果 :外周血CD34+细胞绝对计数与移植物CD34+/kg高度相关 (r=0 790 ,P <0 0 0 1) ,外周血CD34+细胞百分比与移植物CD34+/kg相关 (r=0 6 17,P <0 0 5 )。外周血WBC、MNC、NEU、PLT或RBC与移植物CD34+/kg无关。外周血CD34+细胞绝对计数与移植物CFU E相关 ,而与CFU GM无关。外周血MNC与移植物MNC/kg相关。 ( 2 )逐步回归分析结果 :移植物CD34+/kg只与外周血CD34+细胞绝对计数高度相关 (P <0 0 0 1) ,而与外周血CD34+细胞百分比无关。结论　移植物CD34+/kg只与外周血CD34+细胞绝对计数高度相关 ,外周血CD34+细胞绝对计数能够可靠预示自体外周血干细胞的采集效果     

VLA-4整联蛋白和造血细胞迁移之间的相关关系研究

为了阐明VLA-4(CD49d)和造血细胞迁移方向之间的相关关系，将重组人G—CSF稀释后注射于小鼠皮下，以流式细胞仪检到不同时间后Sca-1^ 细胞表面CD49d的表达，并分析Sca-1^ 细胞计数与CD49d表达之间的相关关系。结果表明，注射G—CSF后骨髓和外周血的CD49d的表达都明显下降，同时在第7—9天外周血Sca-1^ 细胞数达到高峰，骨髓有核细胞数下降。而随着CD49d的表达回升，外周血Sca-1^ 细胞数下降，骨髓细胞数却又有增多趋势。结论：VLA-4介导造血细胞与骨髓微环境的粘附，调节CD49d的表达可能合导致造血细胞在骨髓和外周血之间相互迁移。     

抗TGF-β抗体对人脐血CD34+细胞体外扩增及黏附分子表达的影响

本研究的目的是证实抗TGF-β抗体在人脐血CD34 细胞体外扩增过程中可以增加CD34 细胞的扩增效率,并观察其对脐血CD34 细胞粘附分子表达的影响。从6份新鲜脐血标本中富集CD34 细胞,将其接种于含抗TGF-β抗体 SCF Flt-3L TPO IL-3因子组合的SFEM无血清培养体系中,培养6天后,细胞计数,并用FACS检测CD34、c-kit(CD117)、CD11a、CD49d、CD33表达情况,同时进行集落分析。结果表明:①实验组有核细胞数、CD34 细胞数、CD34 c-kit 细胞数及CFU-GEMM分别扩增了41.82±13.49,15.62±6.95,13.36±6.12,11.07±4.05倍,明显高于对照组(P分别=0.001,0.002,0.003,0.002),其中实验组中更为早期的CD34 c-kit-亚群的扩增倍数更多(69.10±41.06),多于有核细胞、CD34 细胞、CD34 c-kit 细胞的扩增倍数(P=0.024)。②TGF-β抗体对CD11a和CD49d的表达无明显影响(P值均大于0.05)。结论:抗TGF-β抗体可协同早期干细胞生长因子有效扩增脐血CD34 细胞,同时不降低CD34 细胞黏附分子的表达。     

慢性B淋巴细胞白血病患者免疫表型及其淋巴细胞亚群和NK细胞的分析

本研究评价慢性B淋巴细胞白血病（B—CLL）患者骨髓（BM）或外周血（PB）白血病细胞的免疫表型及外周血T淋巴细胞亚群和NK细胞在B-CLL诊断、治疗和预后中的应用价值。收集67例B—CLL患者外周血或骨髓标本,应用多参数流式细胞术进行测定。结果表明：67例B—CLL患者外周血淋巴细胞比例明显增加,CD3、CD4、cD8和NK细胞各项指标均极度减低,与正常人相比有显著差异（P〈0．01）,而CD4／CD8比值与正常人相比无显著差异（P〉0．05）。在这些患者中CD19阳性率最高（91．04％）,其他抗原表达阳性率依次为CD5（80．60％）,CD20（76．12）．cyCD79a（74．63％）,CD38（43．28％）,CD11c（42．86％）,CD7（41．94％）,ZAP-70（39．29％）,CD25（0．00％）,CD5和CD19双阳性者占72．73％,CD38与ZAP-70表达有相关性（P〈0．05）。结论：测定B-CLL患者外周血或骨髓白血病细胞的免疫表型、外周血淋巴细胞亚群及NK细胞对于B—CLL的诊断有重要意义。     

No discrepancy between in vivo gene marking efficiency assessed in peripheral blood populations compared with bone marrow progenitors or CD34+ cells

Reports of 1- to 2-log higher gene transfer levels in purified CD34+ cells or marrow CFU compared with levels in mature circulating blood cells after transplantation of retrovirally transduced primitive human hematopoietic cells have resulted in concern that transduced progenitors do not contribute proportionally to ongoing hematopoiesis (Kohn et al., 1995; Brenner, 1996). To study the issue in a relevant large animal, we analyzed samples of mature blood cells, marrow CD34-enriched cells and marrow CD34-depleted cells, and marrow CFU from a cohort of 11 rhesus transplanted with retrovirally transduced cells and followed for up to 5.5 years. They were transplanted with CD34-enriched bone marrow (BM) or G-CSF/SCF-mobilized peripheral blood (PB) cells transduced with vectors containing either neo, human glucocerebrosidase, or murine adenosine deaminase genes. There were no significant differences between the levels of vector sequences found in BM CD34+ cells, BM CD34- cells, PB granulocytes, or PB mononuclear cells (MNCs) in any animal. In four animals transplanted with SCF/G-CSF-primed BM cells and analyzed 3-6 months posttransplantation, the percentage of CFU containing the neo vector appeared to be 1 log higher than the representation of marked cells in the PB of these animals, but this discrepancy did not persist at time points greater than 6 months posttransplantation. The level of CFU marking was no higher than PB granulocyte or MNC marking at any time points in the other animals. Low levels of mature gene-modified cells probably reflect poor transduction of repopulating stem cells, not a block in differentiation or specific immune rejection of mature cells. This study represents the longest follow-up of primates transplanted with transduced hematopoietic cells, and it is encouraging that the levels of vector-containing cells appear stable for up to 5 years.     

Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients

BACKGROUND: HIV-1 infection has been associated with high expression of CD38 on peripheral blood (PB) CD8+ and CD4+ T-cells, which has been related with poor prognosis in untreated HIV-1+ patients. In turn, CD38 expression on PB monocytes from HIV-1+ individuals and its behavior after starting antiretroviral therapy (ART) have been poorly studied. METHODS: CD38 expression on PB CD8+ and CD4+ T-lymphocytes and monocytes was prospectively analyzed in 30 ART-naive HIV-1+ patients, using a quantitative multiparameter flow cytometry approach. Patients were tested prior to therapy, and at weeks +2, +4, +8, +12, and +52 after ART. RESULTS: Prior to ART, CD38 expression was significantly increased on PB CD8+ and CD4+ T-cells and monocytes; despite a significant decrease after ART, CD38 expression remained abnormally high on PB CD8+ T-cells and monocytes, even after one year of therapy, in the absence of detectable plasma viral load. The ART-induced early changes on CD38 expression by PB T-cells and monocytes differed among the cell subsets analyzed and patient groups, probably reflecting an interaction between the direct effects of therapy and a redistribution of the PB compartments of T-cells and monocytes. Hierarchical clustering analysis showed that the overall pattern of changes in CD38 expression observed early after starting ART was predictive of a better response to therapy, not only for PB CD8+ T-cells, but also for CD4+ T-cells and monocytes. Accordingly, those HIV-1+ patients, who experienced a more pronounced increase in CD38 expression on both PB CD4+ T-cells and monocytes after 2 weeks of ART, showed a more rapid viral clearance, which might reflect decreased HIV-1 replication in lymph nodes and other tissues, and a partial restoration of hematopoiesis. CONCLUSIONS: Combined quantitative measurement of CD38 expression on PB monocytes, and CD8+ and CD4+ T-cells is a more useful tool for monitoring HIV-1+ patients under ART, rather than quantitation of CD38 expression on PB CD8+ T-lymphocytes alone.     

脐血干/祖细胞短期体外扩增后归巢相关粘附特性的研究

探讨体外扩增对脐血（UCB)造血干／祖细胞(HSPC)原有粘附功能的影响。将从新鲜UCB标本中纯化的CD34^ 细胞接种于无血清、无基质的悬浮扩增体系，分别于培养第7天、第10天和第14天从扩增产物中再次纯化CD34^ 细胞，比较扩增前后CD34^ 细胞表面VLA—4(CD49d)、VLA—5(CD49e)、LFA—l(CDlla)、L-selecin(CD62L)、PECAM—l(CD3l)、ICAM—l(CD54)和HCAM(CD44)等归巢相关粘附分子(SAMs)的表达情况，并检测CD34^ 细胞与纤连蛋白(FN)间的自发粘附率和基质细胞来源因子—l(SDF—1)诱导粘附率。①在第14天的培养扩增中，表达上述CAMs的各CD34^ 细胞亚群均有不同程度(15～72倍)的扩增；②扩增后CD34^ 细胞表面粘附分子CD44、CD11a、CD49e和CD49d的表达与原代CD34^ 细胞持平或高于培养开时水平，而CD62L、CD54和CD31的表达则有不同程度下调；③在前10d的扩增中，CD34^ 细胞与FN间的自发粘附率和SDF—l诱导粘附率均呈上升趋势。所建立的短期培养体系不仅可以支持表达重要CAMs的UCB CD34^ 细胞亚群的有效扩增，而且扩增后的HSPC总体上保持原有的粘附功能。